Modern Architect ·

Franz-Werner Haas

A seasoned pharmaceutical executive leading a pioneering mRNA therapeutics company through clinical development and strategic partnerships.

Country

Germany

Continent

Europe

Industry

Biotechnology, Pharmaceuticals

Role

Chief Executive Officer, CureVac N.V.

Franz-Werner Haas is the CEO of CureVac N.V., a German biopharmaceutical company focused on mRNA technology. He has held various leadership roles within CureVac, transitioning from Chief Operating Officer (COO) and Chief Commercial Officer (CCO) to CEO in 2020. His career spans significant experience in legal, commercial, and operational aspects of the pharmaceutical industry, particularly in biotech.

Biography

Franz-Werner Haas transitioned to Chief Executive Officer of CureVac N.V. in June 2020, following a tenure as Chief Operating Officer and Chief Commercial Officer since 2018. Prior to this, he served as Chief Corporate Officer from 2012 to 2018. His leadership at CureVac has been pivotal in advancing the company's mRNA technology platform, particularly through the COVID-19 pandemic, where CureVac was a prominent participant in vaccine development efforts. Before joining CureVac, Haas held executive positions at various pharmaceutical and biotech companies, including as General Counsel and Head of Legal at SYGNIS Pharma AG, and previously in similar capacities at Sirona Biochem Corp. and the Isar Group. His extensive background in corporate development, intellectual property, and international business transactions has been instrumental in shaping CureVac's strategic direction, securing funding rounds, and forging key collaborations. Notable deals include the strategic partnership with GlaxoSmithKline (GSK) in 2020 for the development of next-generation mRNA vaccines and antibodies, and the 2015 investment from the Bill & Melinda Gates Foundation. His legal training and operational experience provide a comprehensive understanding of the complex regulatory and commercial landscape of the biotechnology industry.

Accomplishments

01Ascended to CEO of CureVac in June 2020, guiding the company through its critical COVID-19 vaccine development phase and subsequent shifts in corporate strategy.
02Led CureVac's initial public offering (IPO) on Nasdaq in August 2020, raising approximately $245 million, providing substantial capital for continued research and development.
03Instrumental in securing the strategic partnership with GlaxoSmithKline (GSK) in July 2020, valued at £104 million (approx. $130 million) initially, for the development of next-generation multivalent mRNA vaccines and monoclonal antibodies.
04Oversaw the expansion of CureVac's manufacturing capabilities and supply chain agreements to support potential large-scale production of mRNA therapeutics and vaccines.
05Played a key role in attracting early significant investments, such as the €45 million (approx. $50 million) investment from the Bill & Melinda Gates Foundation in 2015, validating CureVac's mRNA platform.
06Navigated CureVac through complex clinical trials, particularly the Phase 2b/3 trial for the COVID-19 vaccine candidate CVnCoV, demonstrating resilience in challenging R&D environments.

Lessons for Operators

**Strategic Partnership as a De-Risking and Scaling Mechanism:** Haas's securing of the GSK partnership demonstrates the value of leveraging established pharmaceutical giants for R&D funding, manufacturing scale, and global distribution expertise. This reduces financial burden and accelerates market access for innovative biotech firms.

**Adaptability in Clinical Development:** The experience with CureVac's first-generation COVID-19 vaccine (CVnCoV) highlights the necessity for clinical strategies to adapt rapidly to evolving scientific understanding and competitive landscapes. Pivoting to next-generation vaccine development post-CVnCoV results showcased strategic flexibility.

**Importance of Capital Markets Access:** Leading CureVac's Nasdaq IPO provided critical capital infusion, enabling sustained investment in a highly R&D-intensive industry. Access to public markets is crucial for biotech companies seeking to fund extensive clinical trials and expand infrastructure.

**Integrated Leadership across Functions:** Haas's progression from legal to COO/CCO and then CEO underscores the benefit of leaders possessing a comprehensive understanding of corporate, operational, and commercial aspects. This cross-functional expertise enables more holistic strategic decision-making in complex biotech environments.

**Long-Term Vision in Platform Technology:** CureVac's sustained focus on its mRNA platform, even after setbacks with specific product candidates, illustrates the importance of a long-term vision for foundational technologies. Leaders must champion core capabilities despite short-term challenges.

**Navigating Public Scrutiny in Health Crises:** During the COVID-19 pandemic, Haas and CureVac faced immense public pressure and scrutiny regarding vaccine development. transparent communication and a focus on scientific rigor are essential when operating in such high-stakes, public health-critical domains.

The Operator's Playbook

Key Takeaways

Practical lessons distilled for operators, investors, C-levels, and capital allocators.

Lesson 01

Leverage Partnerships for Portfolio Diversification and Risk Mitigation

For biotech companies, forming strategic alliances with larger pharmaceutical firms like the GSK collaboration allows for the co-development of multiple product candidates, spreading R&D risk and leveraging complementary expertise. This is particularly vital in mRNA technology where diverse applications exist outside a single therapeutic area.

Lesson 02

Mastering the Capital Markets is Critical for Biotech Growth

Haas's successful execution of CureVac's Nasdaq IPO demonstrates that robust capital market strategies are non-negotiable. Biotech ventures require substantial, continuous funding to progress from discovery to commercialization. Entrepreneurs and leaders must prioritize investor relations and a clear value proposition for public and private financing.

Lesson 03

Embrace Agility in R&D and Clinical Strategy

The highly dynamic nature of pharmaceutical R&D, as seen with CureVac's COVID-19 vaccine program, demands organizational and strategic agility. Recognizing when to pivot, re-evaluate, and innovate based on clinical data or market changes is paramount to efficient resource allocation and long-term success. Static development plans are a liability.

Lesson 04

Interdisciplinary Leadership Drives Biopharma Success

Haas's background spanning legal, operational, and commercial roles before becoming CEO highlights the advantage of leaders with a broad functional understanding. In biopharma, navigating intellectual property, regulatory affairs, manufacturing, and commercialization requires a holistic perspective that can integrate diverse departmental needs and objectives.

Lesson 05

Sustain Investment in Core Platform Technology

CureVac's consistent commitment to its mRNA technology platform, even with particular product outcomes, exemplifies investing in core technological capabilities. Leaders should ensure that the underlying innovative platform is continuously improved and adapted, as it forms the basis for future product pipelines and differentiates the company.

Mental Models

Frameworks & Principles

Named frameworks and strategic principles they popularized or embodied.

Biotech Partnership Model

A strategic approach where smaller, innovative biotech companies collaborate with larger pharmaceutical firms to share R&D costs, leverage manufacturing and distribution networks, and access broader scientific expertise. This often involves licensing agreements, co-development deals, or equity investments.

When to useWhen a biotech company possesses promising early-stage technology but lacks the resources, infrastructure, or market access for full-scale development and commercialization. Useful for de-risking pipelines and accelerating market entry.

Platform Technology Incubation Strategy

Focusing organizational resources on the development and continuous improvement of a foundational technology platform (e.g., mRNA, gene editing) rather than solely on individual product candidates. This strategy aims to generate a pipeline of diverse therapeutics from a core innovation.

When to useApplicable for companies with revolutionary base technologies that have multiple potential applications across various disease areas. Requires long-term investment and a tolerance for individual product setbacks, as platform robustness is the primary goal.

Dual-Track Financing Strategy (Private & Public)

Utilizing both private funding (e.g., venture capital, foundation grants) and public market offerings (e.g., IPOs, follow-on offerings) to meet escalating capital demands throughout the company's lifecycle. This provides flexibility and access to different investor pools.

When to useEssential for high-growth, high-R&D intensity industries like biotechnology, where capital needs can fluctuate significantly from discovery to commercialization. Allows companies to optimize valuation and capital access at different development stages.

Adjacent Minds